株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

慢性腎臓病(CKD)に伴う高リン血症:パイプライン製品の分析

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 224544
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.78円で換算しております。
Back to Top
慢性腎臓病(CKD)に伴う高リン血症:パイプライン製品の分析 Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016
出版日: 2016年12月30日 ページ情報: 英文 58 Pages
概要

高リン酸塩血症(異常に高い血清リン酸塩濃度)は、リン酸塩の摂取の増加、リン酸塩排出の減少、あるいは細胞内リン酸塩を細胞外間隙へ移すという障害に起因していることがあります。この症状は慢性腎臓病患者の中に最も多くみられます。症候は、疲労、吐き気、睡眠障害、息切れ、骨と関節の痛み、かゆみと発疹などが見られます。治療はリン吸着剤と利尿剤を処置します。

当レポートでは、慢性腎臓病に伴う高リン血症に対する治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

慢性腎臓病に伴う高リン血症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

慢性腎臓病に伴う高リン血症:企業で開発中の治療薬

慢性腎臓病に伴う高リン血症:パイプライン製品の概況

  • 後期段階の製品
  • 後期段階の製品
  • 初期段階の製品

慢性腎臓病に伴う高リン血症:企業で開発中の製品

慢性腎臓病に伴う高リン血症:大学/機関で研究中の製品

慢性腎臓病に伴う高リン血症の治療薬開発に従事している企業

  • 3SBio Inc.
  • Ardelyx, Inc.
  • 第一三共
  • Medice Arzneimittel Putter GmbH & Co. KG
  • OPKO Health, Inc.
  • Panion & Bf Biotech Inc
  • Shield Therapeutics Plc
  • Spectrum Pharmaceuticals, Inc.
  • 東レ

慢性腎臓病に伴う高リン血症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

慢性腎臓病に伴う高リン血症:休止中のプロジェクト

慢性腎臓病に伴う高リン血症:開発が中止された製品

慢性腎臓病に伴う高リン血症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8857IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperphosphatemia In Chronic Kidney Disease Overview
  • Therapeutics Development
    • Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Overview
    • Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis
  • Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Development by Companies
  • Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Investigation by Universities/Institutes
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hyperphosphatemia In Chronic Kidney Disease - Products under Development by Companies
  • Hyperphosphatemia In Chronic Kidney Disease - Products under Investigation by Universities/Institutes
  • Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • Ardelyx Inc
    • Daiichi Sankyo Company Ltd
    • Medice Arzneimittel Putter GmbH & Co KG
    • OPKO Health Inc
    • PDX Pharmaceuticals LLC
    • Shield Therapeutics Plc
    • Spectrum Pharmaceuticals Inc
    • Toray Industries Inc
  • Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • DS-2330 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fermagate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JPH-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • niacinamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDX-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PT-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sevelamer carbonate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Phosphate for Hyperphosphatemia In Chronic Kidney Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPI-014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tenapanor hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRK-390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects
  • Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products
  • Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones
    • Featured News & Press Releases
      • May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia
      • Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
      • Jan 07, 2013: Spectrum Pharma Announces Positive RenaZorb Phase I Clinical Data Demonstrating Robust Activity In Easy-to-swallow Pill Formulation
      • May 29, 2012: Spectrum Pharma Announces Enrollment Of First Group Of Patients In Phase I Clinical Trial Of RenaZorb
      • Dec 05, 2011: Spectrum Pharmaceuticals Files Investigational New Drug Application With FDA For SPI-014
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2016
  • Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by 3SBio Inc, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Medice Arzneimittel Putter GmbH & Co KG, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by PDX Pharmaceuticals LLC, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Toray Industries Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H2 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2016
  • Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top